Technical Analysis for MEIP - MEI Pharma, Inc.

Grade Last Price % Change Price Change
grade B 2.35 0.00% 0.00
MEIP closed up 1.95 percent on Wednesday, February 19, 2020, on 51 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical MEIP trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 50 DMA Bullish 1.95%
Pocket Pivot Bullish Swing Setup 1.95%
Oversold Stochastic Weakness 1.95%
50 DMA Resistance Bearish 9.81%
Stochastic Reached Oversold Weakness 9.81%
Down 3 Days in a Row Weakness 9.81%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Medicine Cancer Clinical Medicine Treatment Of Cancer Virotherapy Seattle Genetics Kite Pharma Hematologic Disorders Refractory Solid Tumors

Is MEIP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.41
52 Week Low 1.44
Average Volume 624,177
200-Day Moving Average 2.11
50-Day Moving Average 2.21
20-Day Moving Average 2.33
10-Day Moving Average 2.35
Average True Range 0.15
ADX 16.12
+DI 22.65
-DI 17.91
Chandelier Exit (Long, 3 ATRs ) 2.12
Chandelier Exit (Short, 3 ATRs ) 2.59
Upper Bollinger Band 2.52
Lower Bollinger Band 2.14
Percent B (%b) 0.55
BandWidth 15.99
MACD Line 0.02
MACD Signal Line 0.04
MACD Histogram -0.0208
Fundamentals Value
Market Cap 86.8 Million
Num Shares 36.9 Million
EPS 0.07
Price-to-Earnings (P/E) Ratio 33.57
Price-to-Sales 4.35
Price-to-Book 1.98
PEG Ratio 23.80
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.50
Resistance 3 (R3) 2.50 2.46 2.48
Resistance 2 (R2) 2.46 2.42 2.46 2.47
Resistance 1 (R1) 2.40 2.39 2.43 2.40 2.46
Pivot Point 2.36 2.36 2.37 2.36 2.36
Support 1 (S1) 2.30 2.32 2.33 2.30 2.24
Support 2 (S2) 2.26 2.29 2.26 2.23
Support 3 (S3) 2.20 2.26 2.23
Support 4 (S4) 2.20